Regen BioPharma, Inc.
RGBP
$0.055
$0.0011.85%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | 0.17% | 0.47% | 0.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | 0.00% | 0.17% | 0.47% | 0.47% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00% | 0.00% | 0.17% | 0.47% | 0.47% |
| SG&A Expenses | -29.56% | -34.55% | -38.37% | -38.28% | 137.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.12% | -34.79% | -35.37% | -37.54% | 60.58% |
| Operating Income | 39.11% | 46.12% | 47.35% | 50.38% | -102.30% |
| Income Before Tax | -174.99% | -166.08% | -101.31% | -157.80% | -52.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -174.99% | -166.08% | -101.31% | -157.80% | -52.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -174.99% | -166.08% | -101.31% | -157.80% | -52.67% |
| EBIT | 39.11% | 46.12% | 47.35% | 50.38% | -102.30% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -171.77% | -165.22% | -101.17% | -114.93% | -84.26% |
| Normalized Basic EPS | -146.92% | -161.77% | -100.85% | -111.26% | -83.49% |
| EPS Diluted | -171.77% | -165.22% | -101.17% | -114.93% | -84.26% |
| Normalized Diluted EPS | -146.92% | -161.77% | -100.85% | -111.26% | -83.49% |
| Average Basic Shares Outstanding | 30.82% | 39.06% | 34.00% | -1.76% | -0.86% |
| Average Diluted Shares Outstanding | 30.82% | 39.06% | 34.00% | -1.76% | -0.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |